Cell kinetics in vivo of human breast cancer

British Journal of Surgery

Volumn 83, Issue 1, 1996, Pages 98-102

  Stanton, P D ^a   Cooke, T G ^a   Forster, G ^a   Smith, D ^a   Going, J J ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE;

ARTICLE; BREAST CANCER; CELL KINETICS; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

BREAST NEOPLASMS; BROMODEOXYURIDINE; CELL DIVISION; FEMALE; FLOW CYTOMETRY; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; PLOIDIES; S PHASE;

EID: 0030067696     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800830130     Document Type: Article

References (29)

1. Johnson HA, Bond VP. A method of labeling tissues with tritiated thymidine in vivo and its use in comparing rates of cell proliferation in duct epithelium, fibroadenoma, and carcinoma of human breast. Cancer 1961; 14: 639-43.
2. Hedley DW, Freidlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983; 31: 1333-5.
3. Silvestrini R, Daidone MG, Gasparini G. Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 1985; 56: 1982-7.
4. Meyer JS, Province M. Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat 1988; 12: 191-204.
5. Tubiana M, Pejovic MH, Chavaudra N, Contesso G, Malaise EP. The long-term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer 1984; 33: 441-5.
6. Frierson HF Jr. Ploidy analysis and S-phase fraction determination by flow cytometry of invasive adenocarcinomas of the breast. Am J Surg Pathol 1991; 15: 358-67.
7. Cooke TG, Stanton PD, Winstanley J et al. Long-term prognostic significance of thymidine labelling index in primary breast cancer. Eur J Cancer 1992; 28: 424-6.
8. Stanton PD, Cooke TG, Oakes SJ et al. Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer. Br J Cancer 1992; 66: 925-9.
9. Dean PN, Dolbeare F, Gratzner H, Rice GC, Gray JW. Cell cycle analysis using a monoclonal antibody to BrdUrd. Cell and Tissue Kinetics 1984; 17: 427-36.
10. Begg AC, McNally NJ, Shrieve DC, Kärcher H. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 1985; 6: 620-6.
11. White RA, Terry NHA, Meistrich ML, Calkins DP. Improved method for computing potential doubling time from flow cytometric data. Cytometry 1990; 11: 314-17.
12. Riccardi A, Danova M, Dionigi P et al. Cell kinetics in leukaemia and solid tumours studied with in vivo bromodeoxyuridine and flow cytometry. Br J Cancer 1989; 59: 898-903.
13. Rew DA, Wilson GD, Taylor I, Weaver PC. Proliferation characteristics of human colorectal carcinoma measured in vivo. Br J Surg 1991; 78: 60-6.
14. Rew DA, Campbell ID, Taylor I, Wilson GD. Proliferation indices of invasive breast carcinomas after in vivo 5-bromo2′-deoxyuridine labelling: a flow cytometric study of 75 tumours. Br J Surg 1992; 79: 335-9.
15. Dolbeare F, Gratzner H, Pallavicini MG, Gray JW. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci USA 1983; 80: 5573-7.
16. Baisch H, Gohde W, Linden WA. Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Radiat Environ Biophys 1975; 12: 31-9.
17. Going JJ, Stanton PD, Cooke TG. Influences on measurement of cellular proliferation by histology and flow cytometry in mammary carcinomas labelled in vivo with bromodeoxyuridine. Am J Clin Pathol 1993; 100: 218-22.
18. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; i: 307-10.
19. Forster G, Cooke TG, Cooke LD, Stanton PD, Bowie G, Stell PM. Tumour growth rates in squamous carcinoma of the head and neck measured by in vivo bromodeoxyuridine incorporation and flow cytometry. Br J Cancer 1992; 65: 698-702.
20. Winstanley J, Cooke T, Murray GD et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 1991; 63: 447-50.
21. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
22. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991; 51: 944-8.
23. Anbazhagan R, Gelber RD, Bettelheim R, Goldhirsch A, Gusterson BA. Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. Ann Oncol 1991; 2: 47-53.
24. Barnes DM, Meyer JS, Gonzalez JG, Gullick WJ, Millis RR. Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. Breast Cancer Res Treat 1991; 18: 11-17.
25. Kallioniemi O-P, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991; 49: 650-5.
26. Tommasi S, Paradiso A, Mangia A et al. Biological correlation between HER-2/neu and proliferative activity in human breast cancer. Anticancer Res 1991; 11: 1395-400.
27. Ohyama S, Yonemura Y, Miyazaki I. Prognostic value of S-phase fraction and DNA ploidy studied with in vivo administration of bromodeoxyuridine on human gastric cancers. Cancer 1990; 65: 116-21.
28. Wilson GD. Assessment of human tumor proliferation using bromodeoxyuridine - current status. Acta Oncol 1991; 30: 903-10.
29. Lochrin CA, Wilson GD, McNally NJ, Dische S, Saunders MI. Tumor cell kinetics, local tumor control, and accelerated radiotherapy: a preliminary report. Int J Radiat Oncol Biol Phys 1992; 24: 87-91.